Targeting tumor vascular endothelium: An emerging concept for cancer therapy

Drug Development Research

Volumn 69, Issue 6, 2008, Pages 340-351

  Dhanabal, Mohanraj ^a   Karumanchi, S Ananth ^b   Sukhatme, Vikas P ^b  

^a EMD SERONO INC   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Anti angiogenesis inhibitors; Functional genomics; Targeted screening; Vascular target

Indexed keywords

5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BCR ABL PROTEIN; BEVACIZUMAB; BORTEZOMIB; CEDIRANIB; CETUXIMAB; CILENGITIDE; COMBRETASTATIN; DASATINIB; ENDOSTAR; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; LAPATINIB; MONOCLONAL ANTIBODY LM 609; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PANITUMUMAB; PAZOPANIB; PEGAPTANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RANIBIZUMAB; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLOCIXIMAB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BRAIN EDEMA; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; FUNCTIONAL GENOMICS; HUMAN; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CANCER; LEUKOENCEPHALOPATHY; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NONHUMAN; OVARY CANCER; PROTEINURIA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID DISEASE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

EID: 57749088608     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20266     Document Type: Review

References (147)

1. Aebersold R, Mann M. 2003. Mass spectrometry-based proteomics. Nature 422:198-207.
2. Ambros V. 2003. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 113:673-676.
3. Awada A, Mano M, Hendlisz A, Piccart M. 2004. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert Rev Anticancer Ther 4:53-60.
4. Barcellos-Hoff MH, Ravani SA. 2000. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60:1254-1260.
5. Bartel DP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297.
6. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. 2003. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295.
7. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. 2003. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63:4342-4346.
8. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. 2006. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6:835-845.
9. Bhowmick NA, Neilson EG, Moses HL. 2004. Stromal fibroblasts in cancer initiation and progression. Nature 432:332-337.
10. Bouck N, Stellmach V, Hsu SC. 1996. How tumors become angiogenic. Adv Cancer Res 69:135-174.
11. Bouzin C, Feron O. 2007. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Update 10:109-120.
12. Brindle K. 2008. New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8:94-107.
13. Bruneel A, Labas V, Mailloux A, Sharma S, Vinh J, Vaubourdolle M, Baudin B. 2003. Proteomic study of human umbilical vein endothelial cells in culture. Proteomics 3:714-723.
14. Burrows FJ, Thorpe PE. 1994. Vascular targeting - a new approach to the therapy of solid tumors. Pharmacol Ther 64:155-174.
15. Calin GA, Croce CM. 2006. MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866.
16. Campochiaro PA. 2006. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther 13:559-562.
17. Cao Y. 2001. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 33:357-369.
18. Carmeliet P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395.
19. Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407:249-257.
20. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. 2001. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61:6649-6655.
21. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. 2005. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309.
22. Childs S, Chen JN, Garrity DM, Fishman MC. 2002. Patterning of angiogenesis in the zebrafish embryo. Development 129:973-982.
23. Classen J, Budach W. 2003. Antiangiogenesis and radiotherapy: what is the role of combined modality treatment? Curr Med Chem Anticancer Agents 3:375-382.
24. Cockerill GW, Gamble JR, Vadas MA. 1995. Angiogenesis: models and modulators. Int Rev Cytol 159:113-160.
25. Colman WR, Mousa AS, Monaco DA; Temple University, assignee. 2000. Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5. US patent no. WO0027415.
26. Colman WR, Mousa AS, Monaco DA; Temple University, assignee. 2001. Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5. US patent no. WO0134195.
27. Connell RD, Beebe JS. 2001. Patent focus on cancer chemotherapeutics. II. Angiogenesis agents: April 2000-September 2000. Expert Opin Ther Patents 11:77-114.
28. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420:860-867.
29. Cristofanilli M, Charnsangavej C, Hortobagyi GN. 2002. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov 1:415-426.
30. Cunha GR, Hayward SW, Wang YZ, Ricke WA. 2003. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 107:1-10.
31. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. 2000. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 18:1185-1190.
32. Datamonitor. 2007. Pipeline insight: molecular targeted cancer therapies, can anything else revolutionize the market? Report DMHC2330.
33. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. 2006. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338.
34. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK. 2006. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664.
35. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A. 2006. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 38:1060-1065.
36. Dhanabal M, Jeffers M, Larochelle WJ. 2005. Anti-angiogenic therapy as a cancer treatment paradigm. Curr Med Chem Anticancer Agents 5:115-130.
37. Duda DG, Jain RK, Willett CG. 2007. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033-4042.
38. Durr E, Yu J, Krasinska KM, Carver LA, Yates JR, Testa JE, Oh P, Schnitzer JE. 2004. Direct proteomic mapping of the lung microvascular endothelial cell surface in vivo and in cell culture. Nat Biotechnol 22:985-992.
39. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara L, Barisoni L, Alpers CE, Quaggin SE. 2008. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129-1136.
40. Esquela-Kerscher A, Slack FJ. 2006. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6:259-269.
41. Eto M, Bennouna J, Hunter OC, Lotze MT, Amoscato AA. 2006. Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int J Urol 13:148-156.
42. Ezekowitz RA, Mulliken JB, Folkman J. 1992. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456-1463.
43. Favre CJ, Mancuso M, Maas K, McLean JW, Baluk P, McDonald DM. 2003. Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. Am J Physiol Heart Circ Physiol 285:H1917-1938.
44. Ferrara N. 2000. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 55:15-35.
45. Ferrara N, Alitalo K. 1999. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5:1359-1364.
46. Ferrara N, Hillan KJ, Gerber HP, Novotny W. 2004. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400.
47. Ferrara N, Mass RD, Campa C, Kim R. 2007. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 58:491-504.
48. Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, Clezardin P, Cabon F. 2003. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 63:3919-3922.
49. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
50. Folkman J. 1974a. Tumor angiogenesis. Adv Cancer Res 19:331-358.
51. Folkman J. 1974b. Tumor angiogensis: role in regulation of tumor growth. Symp Soc Dev Biol 30:43-52.
52. Folkman J. 1992. Angiogenesis - retrospect and outlook. Exs 61:4-13.
53. Folkman J. 1995. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763.
54. Folkman J. 1997. Angiogenesis and angiogenesis inhibition: an overview. Exs 79:1-8.
55. Folkman J. 2003. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2(4 Suppl 1):S127-133.
56. Folkman J. 2007. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286.
57. Fukumura D, Jain RK. 2007. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res 74:72-84.
58. Gasparini G. 2001. Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2:733-740.
59. Gerber HP, Wu X, Yu L, Wiesmann C, Liang XH, Lee CV, Fuh G, Olsson C, Damico L, Xie D, Meng YG, Gutierrez J, Corpuz R, Li B, Hall L, Rangell L, Ferrando R, Lowman H, Peale F, Ferrara N. 2007. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 104:3478-3483.
60. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. 2007. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56:641-648.
61. Gille J. 2006. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 15:175-186.
62. Glusker P, Recht L, Lane B. 2006. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982.
63. Goh PP, Sze DM, Roufogalis BD. 2007. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 7:743-758.
64. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, Sukhatme VP, Soff GA, Kufe DW, Weichselbaum RR. 1998. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58:5686-5689.
65. Griffioen AW, van der Schaft DW, Barendsz-Janson AF, Cox A, Struijker Boudier HA, Hillen HF, Mayo KH. 2001. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 354(Pt 2):233-242.
66. Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. 2005. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 11:2662-2669.
67. Habeck H, Odenthal J, Walderich B, Maischein H, Schulte-Merker S. 2002. Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. Curr Biol 12:1405-1412.
68. Hannon GJ, Rossi JJ. 2004. Unlocking the potential of the human genome with RNA interference. Nature 431:371-378.
69. Harris AL. 1997. Antiangiogenesis for cancer therapy. Lancet 349(Suppl 2):SII13-15.
70. Heinzerling JH, Huerta S. 2006. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63:334-337.
71. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. 2003. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 63:8408-8413.
72. Holash J, Wiegand SJ, Yancopoulos GD. 1999. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356-5362.
73. Jacobson BS, Stolz DB, Schnitzer JE. 1996. Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nat Med 2:482-484.
74. Jain RK. 2005. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62.
75. Jain RK. 2008. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8:309-316.
76. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer Statistics. 2008. CA: Cancer J. Clin 58:71-96.
77. Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL, Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L, Sukhatme VP. 2001. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 7:811-822.
78. Kerbel RS. 2004. Antiangiogenic drugs and current strategies for the treatment of lung cancer. Semin Oncol 31(1 Suppl 1):54-60.
79. Kerbel RS. 2008. Tumor angiogenesis. N Engl J Med 358:2039-2049.
80. Kerbel RS, Kamen BA. 2004. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436.
81. Khosravi Shahi P, Fernandez Pineda I. 2008. Tumoral angiogenesis: review of the literature. Cancer Invest 26:104-108.
82. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY, Ansari AM, Scaria PV, Woodle MC, Lu P, Rouse BT. 2004. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 165:2177-2185.
83. Korherr C, Gille H, Schafer R, Koenig-Hoffmann K, Dixelius J, Egland KA, Pastan I, Brinkmann U. 2006. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 103:4240-4245.
84. Korn R, Rohrig S, Schulze-Kremer S, Brinkmann U. 2005. Common denominator procedure: a novel approach to gene-expression data mining for identification of phenotype-specific genes. Bioinformatics 21:2766-2772.
85. Le Tourneau C, Siu LL. 2008. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Curr Opin Oncol 20:256-263.
86. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201.
87. Madhusudan S, Harris AL. 2002. Drug inhibition of angiogenesis. Curr Opin Pharmacol 2:403-414.
88. Maeshima Y, Colorado PC, Kalluri R. 2000a. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 275:23745-23750.
89. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R. 2000b. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 275:21340-21348.
90. Mantovani A, Sozzani S, Vecchi A, Introna M, Allavena P. 1997. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb Haemost 78:406-414.
91. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR. 1998. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291.
92. Mauriz JL, Gonzalez-Gallego J. 2008. Antiangiogenic drugs: current knowledge and new approaches to cancer therapy. J Pharm Sci 97:4129-4154.
93. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Liberman TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria inn preeclampsia. J Clin Invest 111:649-658.
94. Medina MA, Munoz-Chapuli R, Quesada AR. 2007. Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. J Cell Mol Med 11:374-382.
95. Michiels F, van Es H, van Rompaey L, Merchiers P, Francken B, Pittois K, van der Schueren J, Brys R, Vandersmissen J, Beirinckx F, Herman S, Dokic K, Klaassen H, Narinx E, Hagers A, Laenen W, Piest I, Pavliska H, Rombout Y, Langemeijer E, Ma L, Schipper C, Raeymaeker MD, Schweicher S, Jans M, van Beeck K, Tsang IR, van de Stolpe O, Tomme P, Arts GJ, Donker J. 2002. Arrayed adenoviral expression libraries for functional screening. Nat Biotechnol 20:1154-1157.
96. Million RP. 2008. Therapeutic area cross-roads: anti-angiogenesis. Nat Rev Drug Discov 7:115-116.
97. Mittal V, Nolan DJ. 2007. Genomics and proteomics approaches in understanding tumor angiogenesis. Expert Rev Mol Diagn 7:133-147.
98. Ng EW, Adamis AP. 2005. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40:352-368.
99. Niola F, Evangelisti C, Campagnolo L, Massalini S, Bue MC, Mangiola A, Masotti A, Maira G, Farace MG, Ciafre SA. 2006. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther 5:174-179.
100. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G. 2006. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032-1037.
101. O'Connell MJ. 2004. Current status of adjuvant therapy for colorectal cancer. Oncology (Huntingt) 18:751-755.
102. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE. 2004. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429:629-635.
103. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. 1999. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59:5002-5011.
104. Ozcan C, Wong SJ, Hari P. 2006. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354:980-982.
105. Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD. 2008. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100:282-284.
106. Pietras K, Pahler J, Bergers G, Hanahan D. 2008. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5:e19.
107. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, Mercatanti A, Hammond S, Rainaldi G. 2006. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108:3068-3071.
108. Rafii S. 2000. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 105:17-19.
109. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS. 1995. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55:4575-4580.
110. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K. 2001. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 98:1024-1029.
111. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ. 2003. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210-216.
112. Retter AS, Figg WD, Dahut WL. 2003. The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. Clin Prostate Cancer 2:153-159.
113. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, Yan M. 2006. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444:1083-1087.
114. Ruoslahti E. 2000. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 10:435-442.
115. Ruoslahti E. 2002. Drug targeting to specific vascular sites. Drug Discov Today 7:11381143.
116. Ruoslahti E, Rajotte D. 2000. An address system in the vasculature of normal tissues and tumors. Annu Rev Immunol 18:813-827.
117. Sarmiento R, Gasparini G. 2008. Antiangiogenic metronomic chemotherapy. Onkologie 31:161-612.
118. Sawyers C. 2004. Targeted cancer therapy. Nature 432:294-297.
119. Sawyers CL. 2005. Making progress through molecular attacks on cancer. Cold Spring Harb Symp Quant Biol 70:479-482.
120. Scheurer SB, Rybak JN, Roesli C, Brunisholz RA, Potthast F, Schlapbach R, Neri D, Elia G. 2005. Identification and relative quantification of membrane proteins by surface biotinylation and two-dimensional peptide mapping. Proteomics 5:2718-2728.
121. Shahrzad S, Shirasawa S, Sasazuki T, Rak JW, Coomber BL. 2008. Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts. Oncogene 27:3729-3738.
122. Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Zinnen S, Kossen K, Fosnaugh K, Vargeese C, Gomez A, Bouhana K, Aitchison R, Pavco P, Campochiaro PA. 2006. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther 13:225-234.
123. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N. 2007. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25:911-920.
124. Shu X, Wu W, Mosteller RD, Broek D. 2002. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol 22:7758-7768.
125. Slevin M, Payne S. 2004. New treatments for colon cancer. BMJ 329:124-126.
126. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. 2000. Genes expressed in human tumor endothelium. Science 289:1197-1202.
127. Sund M, Hamano Y, Sugimoto H, Sudhakar A, Soubasakos M, Yerramalla U, Benjamin LE, Lawler J, Kieran M, Shah A, Kalluri R. 2005a. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci USA 102:2934-2939.
128. Sund M, Zeisberg M, Kalluri R. 2005b. Endogenous stimulators and inhibitors of angiogenesis in gastrointestinal cancers: basic science to clinical application. Gastroenterology 129:2076-2091.
129. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen Jr. J, Sledge GW 2001. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372.
130. Tao J, Tu YT, Huang CZ, Feng AP, Wu Q, Lian YJ, Zhang LX, Zhang XP, Shen GX. 2005. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br J Dermatol 153:715-724.
131. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW. 2006. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103:15975-15980.
132. Thijssen VL, van Beijnum JR, Mayo KH, Griffioen AW. 2007. Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango. Curr Pharm Des 13:3576-3583.
133. Thompson LJ, Wang F, Proia AD, Peters KG, Jarrold B, Greis KD. 2003. Proteome analysis of the rat cornea during angiogenesis. Proteomics 3:2258-2266.
134. Thorpe PE. 2004. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427.
135. Tjin Tham Sjin RM, Naspinski J, Birsner AE, Li C, Chan R, Lo KM, Gillies S, Zurakowski D, Folkman J, Samulski J, Javaherian K. 2006. Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13:619-627.
136. Tortora G, Melisi D, Ciardiello F. 2004. Angiogenesis: a target for cancer therapy. Curr Pharm Des 10:11-26.
137. Tosetti F, Benelli R, Albini A. 2002. The angiogenic switch in solid tumors: clinical implications. Suppl Tumori 1:S9-11.
138. Urbich C, Heeschen C, Aicher A, Sasaki K, Bruhl T, Farhadi MR, Vajkoczy P, Hofmann WK, Peters C, Pennacchio LA, Abolmaali LA, Chavakis E, Reinheckel T, Zeiher AM, Dimmeler S. 2005. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 11:206-213.
139. van Beijnum JR, Eijgelaar WJ, Griffioen AW. 2006. Towards high-throughput functional target discovery in angiogenesis research. Trends Mol Med 12:44-52.
140. van Beijnum JR, Griffioen AW. 2005. In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. Biochim Biophys Acta 1755:121-134.
141. van der Schaft DW, Dings RP, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC, Wagstaff J, Mayo KH, Griffioen AW. 2002. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 16:1991-1993.
142. Walter-Yohrling J, Morgenbesser S, Rouleau C, Bagley R, Callahan M, Weber W, Teicher BA. 2004. Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res 10:2179-2189.
143. Wannenes F, Ciafre SA, Niola F, Frajese G, Farace MG. 2005. Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. Cancer Gene Ther 12:926-934.
144. Wilson JF. 2004. Angiogenesis therapy moves beyond cancer. Ann Intern Med 141:165-168.
145. Yancopoulos GD, Klagsbrun M, Folkman J. 1998. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 93:661-664.
146. Yang WJ, Yang DD, Na S, Sandusky GE, Zhang Q, Zhao G. 2005. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 280:9330-9335.
147. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. 2002. Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526-1528.